<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23027" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Human Insulin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dave</surname>
            <given-names>Heeransh D.</given-names>
          </name>
          <aff>Tver State Medical University, Tver, Russian Federation</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heeransh Dave declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23027.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The management of type 1 diabetes mellitus entails replacing the actions of the beta cells of the pancreatic islet to detect the need for insulin and to have insulin administered according to the requirements of the patient's body. This activity reviews the indications for the use of insulin, its mechanism of action, routes of administration, contraindications, adverse effects, monitoring its blood concentrations, and toxicity. It also describes in detail how insulin leads to shifts of electrolytes between the intracellular and extracellular compartments. Also, this activity summarizes the cellular production of insulin and its function via its receptor and the numerous effects on carbohydrate, protein, and fat metabolism.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the action of insulin on glucose metabolism.</p></list-item><list-item><p>Review the synthesis of insulin in pancreatic beta cells.</p></list-item><list-item><p>Outline the relationship between insulin and potassium and its importance in the management of patients with diabetic ketoacidosis.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication about the use of insulin to enhance outcomes for patients affected by diabetes mellitus.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23027&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23027">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23027.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The management of type 1 diabetes mellitus entails replacing the actions of the beta cells of the pancreatic islet to detect the need for insulin and to have insulin administered according to the needs of the patient's body. Insulin is a natural hormone, and it is an essential medication for a multitude of disease states. One of the most critical uses of insulin is in type 1 diabetes mellitus and type 2 diabetes mellitus.<xref ref-type="bibr" rid="article-23027.r1">[1]</xref><xref ref-type="bibr" rid="article-23027.r2">[2]</xref> Insulin is one of the few medications indicated for use in the management of gestational diabetes.<xref ref-type="bibr" rid="article-23027.r3">[3]</xref> Due to its effects of driving potassium into the intracellular compartment, it has utility in managing hyperkalemia.<xref ref-type="bibr" rid="article-23027.r4">[4]</xref> Insulin is a component in the management of complications of diabetes mellitus, including diabetic ketoacidosis as well as the hyperosmolar hyperglycemic state.<xref ref-type="bibr" rid="article-23027.r5">[5]</xref></p>
        <p>There is a proven clinical benefit&#x000a0;in using insulin in critical illnesses to prevent or treat hyperglycemia-related toxicity.<xref ref-type="bibr" rid="article-23027.r6">[6]</xref> Commonly, treatment of hypertriglyceridemia includes dietary modifications and medical management with the use of fibrates, fish oil, and niacin, amongst others. One of the other very important applications of insulin is in the treatment of severe hypertriglyceridemia as well as hypertriglyceridemia-induced pancreatitis. Insulin lowers the triglycerides by upregulating the formation of lipoprotein lipase, which works by hydrolyzing the triglycerides. Insulin infusion can help patients with severe hypertriglyceridemia by quickly reducing the blood concentrations of triglycerides to less than 1000 mg/dl.<xref ref-type="bibr" rid="article-23027.r7">[7]</xref></p>
      </sec>
      <sec id="article-23027.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Insulin&#x02019;s significant actions focus on storing excess energy in a fed state. Insulin promotes glycogen synthesis, lipid synthesis, protein synthesis, DNA synthesis, and cellular growth and differentiation. Once glucose gets absorbed from a meal, it enters the blood, and then the pancreas releases insulin. Insulin synthesis occurs in the beta cells of the pancreas initially as preproinsulin.&#x000a0;Preproinsulin then converts to proinsulin, which then transforms into a single peptide with A, B, and C peptide units. The A and B peptides are joined by disulfide bonds to make insulin and&#x000a0;are secreted into the bloodstream. Insulin binds to its cellular receptor.&#x000a0;The insulin receptor is composed of alpha subunits, beta subunits, and a tyrosine kinase enzyme. When insulin binds to the alpha subunit, this triggers phosphorylation and activation of the target proteins intracellularly by the tyrosine kinase leading to many effects on cellular metabolism. Activation of the insulin receptor also leads to increased expression of GLUT (a glucose transporter) to the membrane surface and promotes the entry of glucose to the intracellular compartment and then undergoes cellular metabolism. Insulin signals glucose conversion to glycogen for storage and the formation of acetyl coenzyme A and triacylglycerol, which get stored in adipose tissue. Also, insulin directs amino acids for protein synthesis.<xref ref-type="bibr" rid="article-23027.r3">[3]</xref></p>
        <p>In patients with diabetes mellitus, to reach the goal of normal 24-hour insulin activity like in healthy adults without diabetes mellitus, one single insulin formulation with a defined onset, peak, and duration of action is not helpful. Hence there is a need for different kinds of insulin that have different pharmacokinetics. Based on the mode of action, there are four different types of insulin analogs as follows<xref ref-type="bibr" rid="article-23027.r8">[8]</xref>:</p>
        <table-wrap id="article-23027.table0" position="float" orientation="portrait">
          <table style="width: 1490.97px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 26px;">
                <td style="width: 509px; height: 26px;" rowspan="1" colspan="1">
<bold>Insulin Type</bold>
</td>
                <td style="width: 250px; height: 26px;" rowspan="1" colspan="1">
<bold>Onset</bold>
</td>
                <td style="width: 140px; height: 26px;" rowspan="1" colspan="1">
<bold>Peak activity</bold>
</td>
                <td style="width: 140px; height: 26px;" rowspan="1" colspan="1">
<bold>Duration</bold>
</td>
                <td style="width: 1381.97px; height: 26px;" rowspan="1" colspan="1">
<bold>Notes</bold>
</td>
              </tr>
              <tr style="height: 47px;">
                <td style="width: 509px; height: 47px;" rowspan="1" colspan="1">Rapid Acting</td>
                <td style="width: 250px; height: 47px;" rowspan="1" colspan="1">Less than 15 minutes</td>
                <td style="width: 140px; height: 47px;" rowspan="1" colspan="1">0.5 to 3 hours</td>
                <td style="width: 140px; height: 47px;" rowspan="1" colspan="1">3 to 5 hours</td>
                <td style="width: 1381.97px; height: 47px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Agents include insulin lispro, insulin aspart, and insulin glulisine</p></list-item><list-item><p>Onset may vary between products for each patient</p></list-item><list-item><p>If mixing with NPH, draw the rapid-acting insulin into the syringe first; give the mixture immediately to avoid effects on peak action</p></list-item><list-item><p>Help to achieve post-prandial glycemic control</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 509px; height: 13px;" rowspan="1" colspan="1">Short-acting (regular) insulin</td>
                <td style="width: 250px; height: 13px;" rowspan="1" colspan="1">0.5 to 1 hour</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">2 to 4 hours</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">4 to 8 hours</td>
                <td style="width: 1381.97px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>May be mixed with NPH in one syringe. Regular insulin (clear) should be drawn into the syringe first, then the NPH (cloudy) - "clear before cloudy."</p></list-item><list-item><p>Administer approximately 30 minutes before meals for the greatest effectiveness.</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 509px; height: 13px;" rowspan="1" colspan="1">Intermediate-acting (NPH) insulin</td>
                <td style="width: 250px; height: 13px;" rowspan="1" colspan="1">2 to 4 hours</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">4 to 10 hours</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">10 to 18 hours</td>
                <td style="width: 1381.97px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Can be administered via a dosing pen or from a vial with a syringe</p></list-item><list-item><p>Insulin Lente and insulin Hagedorn are in this category</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 509px; height: 13px;" rowspan="1" colspan="1">Long-acting insulin and ultra-long-acting</td>
                <td style="width: 250px; height: 13px;" rowspan="1" colspan="1">2 to 3 hours or 4 to 6 hours, depending on the product</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">6 to 8 hours</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">Up to 24 hours (some products can exceed 24 hours)</td>
                <td style="width: 1381.97px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Cannot be mixed in the same syringe with other insulins</p></list-item><list-item><p>Available in pen and vial</p></list-item><list-item><p>Duration of action can be dose-dependant</p></list-item><list-item><p>Agents include insulin glargine and insulin detemir</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 509px; height: 13px;" rowspan="1" colspan="1">70% NPH + 30% regular insulin</td>
                <td style="width: 250px; height: 13px;" rowspan="1" colspan="1">0.5 to 1 hour</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">2 to 10 hours</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">10 to 18 hours</td>
                <td style="width: 1381.97px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Action has 2 peaks; one from each&#x000a0;individual formulation</p></list-item></list>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 509px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>70% aspart protamine + 30% aspart</p></list-item><list-item><p>75% lispro protamine + 25% lispro</p></list-item><list-item><p>50% lispro protamine + 25% lispro</p></list-item></list>
</td>
                <td style="width: 250px; height: 13px;" rowspan="1" colspan="1">Less than 15 minutes</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">1 to 2 hours</td>
                <td style="width: 140px; height: 13px;" rowspan="1" colspan="1">10 to 18 hours</td>
                <td style="width: 1381.97px; height: 13px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Action has 2 peaks; one from each&#x000a0;individual formulation.</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-23027.s4" sec-type="Administration">
        <title>Administration</title>
        <p>There are multiple routes of administration of insulin. Insulin is most commonly injected using an insulin syringe. These are plastic disposable syringes available in sizes that hold 30, 50, and 100 units of insulin. They come equipped with a fine gauge needle (up to 31 gauge) with short needle lengths of 3/16 inch for infants up o 1/2 inch or greater for adults. The most frequent administration method is a subcutaneous injection. In rare instances, insulin may be injected into a muscle, but this should only be under close medical supervision, as in a hospital or other facility.</p>
        <p>Because of their convenience, insulin pens have gained greater popularity in recent years; these can be disposable or re-usable, the latter utilizing disposable insulin cartridges.&#x000a0;Another option is continuous subcutaneous insulin infusion (CSII) devices or insulin pumps. These small computerized devices are programmed to deliver subcutaneous insulin.<xref ref-type="bibr" rid="article-23027.r9">[9]</xref></p>
        <p>Regular insulin and&#x000a0;rapid-acting insulins can also be delivered intravenously, but this is only possible under close medical supervision in a clinical setting.<xref ref-type="bibr" rid="article-23027.r10">[10]</xref></p>
        <p>Administration can be as a bolus as an intravenous injection or as a continuous intravenous infusion. Typically, glycemic control is achieved by using basal and prandial insulin administration or by continuous subcutaneous insulin infusion. Recently, the inhalational route for the administration of insulin is available for clinical use.<xref ref-type="bibr" rid="article-23027.r2">[2]</xref><xref ref-type="bibr" rid="article-23027.r11">[11]</xref> Transplantation of the islet cells of the pancreas or pancreatic transplantation is an investigational procedure that can mimic natural insulin synthesis and functionality.<xref ref-type="bibr" rid="article-23027.r12">[12]</xref> Administration of insulin via oral and transdermal routes is being evaluated and may be available shortly for everyday use.<xref ref-type="bibr" rid="article-23027.r11">[11]</xref></p>
      </sec>
      <sec id="article-23027.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>As with&#x000a0;any other medication, there are clinically significant side effects associated with the use of insulin. Insulin administration can lead to local hypersensitivity reactions such as erythema, pruritus, swelling, and pain at the injection site. Local dermal lipo-dystrophic reactions can occur. An inappropriately excessive dose of insulin or incoordination with meals/missing meals hypoglycemia can occur, which can be life-threatening. Untreated hypoglycemia can cause seizures, coma as well as death, which makes it especially important in elderly patients who are more susceptible. Long-term use of insulin can lead to the production of antibodies against it with the possible development of insulin resistance. As mentioned earlier, insulin can cause the potassium to shift to the intracellular compartment and lead to hypokalemia. Hypokalemia can manifest as cardiac arrhythmias, muscle cramping, gastrointestinal upset, confusion, weakness, and lethargy.<xref ref-type="bibr" rid="article-23027.r11">[11]</xref></p>
      </sec>
      <sec id="article-23027.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are a few contraindications to the use of insulin. A patient history of allergic reactions to insulin, its reuse is contraindicated. In patients with insulinoma, where there is excessive endogenous insulin production, the use of exogenous insulin is contraindicated. There is a relative contraindication to using insulin in the setting of hypokalemia. The potassium concentrations must be corrected before administering insulin, as insulin has a known effect of causing hypokalemia.</p>
      </sec>
      <sec id="article-23027.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is paramount to monitor the blood glucose concentrations while using insulin for optimal glycemic control without causing hypoglycemia (or hyperglycemia). This monitoring is commonly done with regular blood glucose checking with finger prick glucose testing using a glucometer. There are novel techniques now available for continuous glucose monitoring that work via a sensing device inserted subcutaneously. The device measures the glucose concentration in the interstitial fluid between the cells and transmits this information to a monitoring device. The glucose concentrations can be tracked consistently during the day as well as at night with this device. Also, long-term glycemic control can be monitored by using glycated hemoglobin, also known as hemoglobin A1C.</p>
      </sec>
      <sec id="article-23027.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Insulin overdose can cause toxicity by causing hypoglycemia and many additional effects, including arrhythmias, coma, seizures, hypotension, amongst other symptoms. Long-term insulin use may lead to dermal toxicity by causing lipodystrophy. The patient can mitigate this adverse effect by rotating subcutaneous injection sites. Insulin can also cause hypokalemia and related complications, as mentioned earlier in this article.</p>
      </sec>
      <sec id="article-23027.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>To enhance patient health outcomes by the healthcare teams, medical education and dissemination of information regarding diabetes mellitus, its complications, and management options are crucial for patient care. All interprofessional healthcare team members (clinicians, pharmacists, nurses) must be&#x000a0;mindful of the potential complications as well as how to manage hypoglycemia, hypokalemia, and other complications of insulin pharmacotherapy.</p>
        <p>All interprofessional team members should assist in educating the patient and family about the importance of safe insulin dosing. Demonstrations and educational workshops would go a long way toward achieving these goals. It is also crucial to educate the patient to recognize the early signs of hypoglycemia and how to manage diabetes mellitus with insulin and other glycemic control medications. This approach allows the patient to become an integral member of the healthcare team, i.e., its number one focus, and to help in improving overall outcomes by close collaboration. Nursing should ensure proper administration, adherence, and verify monitoring. Pharmacists need to verify dosing, perform medication reconciliation, and instruct patients on administration and how to use their glucose monitor properly. If there are concerns, they should work with the clinician to improve the safe administration of the drug. Monitoring of the blood glucose concentrations, adjusting the dose of insulin as necessary, and lifestyle modifications to prevent chronic complications of diabetes mellitus are significant goals to enhance the patient health outcomes by the healthcare team. [Level 5]</p>
      </sec>
      <sec id="article-23027.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23027&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23027">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23027/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23027">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23027.s11">
        <title>References</title>
        <ref id="article-23027.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathieu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gillard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benhalima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Insulin analogues in type 1 diabetes mellitus: getting better all the time.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>385</fpage>
            <page-range>385-399</page-range>
            <pub-id pub-id-type="pmid">28429780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Molitch</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Insulin therapy for type 2 diabetes mellitus.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Jun</month>
            <day>11</day>
            <volume>311</volume>
            <issue>22</issue>
            <fpage>2315</fpage>
            <page-range>2315-25</page-range>
            <pub-id pub-id-type="pmid">24915263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coustan</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Gestational diabetes mellitus.</article-title>
            <source>Clin Chem</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>9</issue>
            <fpage>1310</fpage>
            <page-range>1310-21</page-range>
            <pub-id pub-id-type="pmid">23536513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harel</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>e0154963</fpage>
            <pub-id pub-id-type="pmid">27148740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhatariya</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Vellanki</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA).</article-title>
            <source>Curr Diab Rep</source>
            <year>2017</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>33</fpage>
            <pub-id pub-id-type="pmid">28364357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanhorebeek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Langouche</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Van den Berghe</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness?</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>304</fpage>
            <page-range>304-11</page-range>
            <pub-id pub-id-type="pmid">16015107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poonuru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Vats</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin.</article-title>
            <source>Clin Med Res</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-41</page-range>
            <pub-id pub-id-type="pmid">20852089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Insulin sources and types: a review of insulin in terms of its mode on diabetes mellitus.</article-title>
            <source>J Tradit Chin Med</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>234</fpage>
            <page-range>234-7</page-range>
            <pub-id pub-id-type="pmid">24783939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Avari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Godsland</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Lett</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Optimizing type 1 diabetes after multiple daily injections and capillary blood monitoring: Pump or sensor first? A meta-analysis using pooled differences in outcome measures.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>2521</fpage>
            <page-range>2521-2528</page-range>
            <pub-id pub-id-type="pmid">34286892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aschner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Insulin Therapy in Type 2 Diabetes.</article-title>
            <source>Am J Ther</source>
            <year>2020</year>
            <season>Jan/Feb</season>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>e79</fpage>
            <page-range>e79-e90</page-range>
            <pub-id pub-id-type="pmid">31567175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matteucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Giampietro</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Covolan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giustarini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2015</year>
            <volume>9</volume>
            <fpage>3109</fpage>
            <page-range>3109-18</page-range>
            <pub-id pub-id-type="pmid">26124635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23027.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gangemi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salehi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hatipoglu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martellotto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barbaro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kuechle</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pallan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oberholzer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Islet transplantation for brittle type 1 diabetes: the UIC protocol.</article-title>
            <source>Am J Transplant</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>1250</fpage>
            <page-range>1250-61</page-range>
            <pub-id pub-id-type="pmid">18444920</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
